Exercise should be prescribed as a foundational component of cardiovascular disease (CVD) prevention and treatment, according to a new American College of Cardiology Scientific Statement published today in… read more.
Travere Therapeutics, Inc. presented new biomarker data from the Phase 3 PROTECT Study providing evidence that FILSPARI (sparsentan) may modify the underlying disease pathophysiology in people with IgA… read more.
According to information published on the European Medicines Agency (EMA) website, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of… read more.
Johnson & Johnson announced new data from the Phase 3 MajesTEC-3 study showing sustained disease control and survival with TECVAYLI (teclistamab-cqyv) plus DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) in… read more.
Someone shopping for an over-the-counter (OTC) hearing aid may have to sort through dozens of products, determine which ones are regulated by the FDA, figure out what insurance… read more.
AbbVie announced new findings from the Phase 3 AFFIRM study evaluating a new option for induction treatment with Skyrizi (risankizumab-rzaa) in adults with moderately to severely active Crohn’s… read more.
Novartis announced that the European Commission (EC) has approved Cosentyx (secukinumab) for the treatment of adults with polymyalgia rheumatica (PMR) who have had an inadequate response to glucocorticoids or… read more.
Eli Lilly and Company announced positive late-breaking one-year results from the Phase 3 SHINE-2 study of Omvoh (mirikizumab-mrkz) in pediatric patients ages 6 to 17 with moderately to… read more.
Enhertu (trastuzumab deruxtecan) has been approved in China as a monotherapy for the treatment of adult patients with unresectable or metastatic solid tumors with HER2 expression (immunohistochemistry [IHC]… read more.
The American Society of Hematology (ASH) released guidelines on the management of myelofibrosis, a rare and life-threatening blood cancer. ASH’s new guidelines recommend expanded molecular testing, early transplant… read more.
The rapid expansion of private testosterone prescribing risks extending treatment beyond men with clearly defined need to people with non-specific symptoms and borderline test results, for whom the… read more.
Bristol Myers Squibb announced first time presentation of results from the prespecified analysis of the pivotal Phase 3 EXCALIBER-RRMM trial (NCT04975997) evaluating ZENBEXUS (iberdomide) in combination with daratumumab… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
